Edition:
United States

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

117.43USD
22 Oct 2018
Change (% chg)

-- (--)
Prev Close
$117.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
104,531
52-wk High
$220.09
52-wk Low
$77.60

Latest Key Developments (Source: Significant Developments)

Beigene Announces Updated Results From Phase 1 Clinical Trial Of Zanubrutinib
Friday, 12 Oct 2018 06:00am EDT 

Oct 12 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE ANNOUNCES UPDATED RESULTS FROM PHASE 1 CLINICAL TRIAL OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA.BEIGENE LTD - FIRST U.S. NDA FILING FOR ZANUBRUTINIB EXPECTED TO FILE IN FIRST HALF OF 2019.BEIGENE LTD - TREATMENT WITH ZANUBRUTINIB WAS GENERALLY WELL-TOLERATED & MAJORITY OF ADVERSE EVENTS WERE GRADE 1 OR 2 IN SEVERITY.BEIGENE LTD - UPDATED RESULTS FROM STUDY INCLUDED THAT OVERALL RESPONSE RATE WAS 92 PERCENT.BEIGENE LTD - 4 PATIENTS DISCONTINUED STUDY TREATMENT DUE TO DISEASE PROGRESSION & 1 PATIENT REMAINS ON TREATMENT POST-DISEASE PROGRESSION.BEIGENE - UPDATED STUDY RESULTS INCLUDED NINE PATIENTS DISCONTINUED DUE TO AES.  Full Article

Beigene Posts HY Net Loss Attributable $261.5 Million
Thursday, 30 Aug 2018 08:00am EDT 

Aug 30 (Reuters) - Beigene Ltd <6160.HK>::HY NET LOSS ATTRIBUTABLE $261.5 MILLION VERSUS LOSS OF $111.2 MILLION.  Full Article

BeiGene Qtrly Net Loss Per ADS $2.19
Wednesday, 28 Feb 2018 04:05pm EST 

Feb 28 (Reuters) - BeiGene Ltd ::BEIGENE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $18.17 MILLION.QTRLY NET LOSS PER ADS $2.19.  Full Article

Beigene Announces Approval Of Revlimid In China
Tuesday, 27 Feb 2018 06:00pm EST 

Feb 27 (Reuters) - Beigene Ltd ::BEIGENE ANNOUNCES APPROVAL OF REVLIMID® FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA.BEIGENE LTD - ‍REVLIMID HAS BEEN APPROVED BY CHINA FOOD AND DRUG ADMINISTRATION FOR TREATMENT OF MULTIPLE MYELOMA​.  Full Article

Beigene Announces Proposed Public Offering
Tuesday, 16 Jan 2018 04:04pm EST 

Jan 16 (Reuters) - Beigene Ltd ::BEIGENE ANNOUNCES PROPOSED PUBLIC OFFERING.BEIGENE LTD - ‍PUBLIC OFFERING OF ITS AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING 13 OF ITS ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE​.BEIGENE LTD - ‍BEIGENE INTENDS TO OFFER AND SELL $650 MILLION OF ITS ADSS, BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES​.  Full Article

Beigene And Boehringer Ingelheim Announce Commercial Supply Agreement For Tislelizumab
Tuesday, 9 Jan 2018 09:00am EST 

Jan 9 (Reuters) - Beigene Ltd ::BEIGENE AND BOEHRINGER INGELHEIM ANNOUNCE COMMERCIAL SUPPLY AGREEMENT FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB.BEIGENE LTD - BOEHRINGER INGELHEIM WILL MANUFACTURE TISLELIZUMAB IN CHINA UNDER AN EXCLUSIVE MULTI-YEAR ARRANGEMENT, WITH CONTRACT EXTENSION POSSIBLE.BEIGENE LTD - CO ALSO OBTAINED CERTAIN PREFERRED RIGHTS FOR FUTURE CAPACITY EXPANSION BY BOEHRINGER INGELHEIM IN CHINA.  Full Article

Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region
Monday, 8 Jan 2018 06:00am EST 

Jan 8 (Reuters) - Beigene Ltd ::BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION.BEIGENE LTD - MIRATI WILL RETAIN EXCLUSIVE RIGHTS FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SITRAVATINIB FOR REST OF WORLD..BEIGENE LTD - UNDER AGREEMENT MIRATI WILL RECEIVE AN UPFRONT CASH PAYMENT OF $10 MILLION FROM BEIGENE.BEIGENE - MIRATI ELIGIBLE TO RECEIVE UP TO $123 MILLION OF EXTRA PAYMENTS UPON CERTAIN DEVELOPMENT, REGULATORY AND SALES MILESTONES, AMONG OTHERS.BEIGENE - CO, MIRATI THERAPEUTICS ENTERED AGREEMENT FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF MIRATI'S SITRAVATINIB IN ASIA.  Full Article

Beigene Ltd qtrly ‍net income attributable to common shareholders per ADS, diluted $2.54​
Monday, 13 Nov 2017 04:05pm EST 

Nov 13 (Reuters) - Beigene Ltd ::Beigene reports third quarter 2017 financial results.Beigene Ltd - qtrly ‍net income attributable to common shareholders per ads, diluted $2.54​.  Full Article

Beigene presents preliminary phase 1 data for bgb-a317
Thursday, 28 Sep 2017 09:00am EDT 

Sept 28 (Reuters) - Beigene Ltd ::Beigene presents preliminary phase 1 data for bgb-a317 in chinese patients with advanced tumors at the 20th annual meeting of CSCO.Beigene Ltd - ‍adverse events assessed by investigator related to treatment occurred in 19 patients​.Beigene - ‍preliminary data suggest that bgb-a317 was generally well tolerated​.Beigene-Preliminary data suggest bgb-a317 exhibited preliminary evidence of anti-tumor activity in chinese study population with advanced solid tumors​.Beigene ltd - ‍intend to initiate phase 3 trials supporting approval in china for each of 4 tumors, lung, stomach, liver, and esophageal cancers​.Beigene ltd - ‍initial studies expected to start in q4 of 2017 or q1 of 2018 for bgb-a317 phase 3 trials​.  Full Article

Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​
Friday, 1 Sep 2017 06:18am EDT 

Sept 1 (Reuters) - Beigene Ltd :Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​.  Full Article

Photo

Chinese biotech BeiGene raises $903 million in HK's first secondary listing under new rules: sources

HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.